SCHEMBL1993263

SCHEMBL1993263

CCc1noc(-c2ccc3c(c2)N(S(=O)(=O)c2ccccc2)CCS3)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 2/20 0.43
RORC P51449 1/20 0.42
ALDH1A1 P00352 3/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
CPT2 P23786 2/20 0.40
CPT1A P50416 2/20 0.40
CPT1B Q92523 2/20 0.40
TP53 P04637 2/20 0.39
CNR1 P21554 1/20 0.37
CNR2 P34972 1/20 0.37
MAPT P10636 2/20 0.37
KDM4E B2RXH2 1/20 0.37
PKM P14618 1/20 0.37
HPGD P15428 1/20 0.37
HSD17B10 Q99714 1/20 0.37
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1995614 0.91 CNR1 (0.48) GPR119RORCALDH1A1CPT2CPT1A
SCHEMBL1996870 0.88 KMT2A (0.43) GPR119RORCSMN1; SMN2CPT2CPT1A
SCHEMBL1996272 0.85 RORC (0.44) GPR119RORCALDH1A1CPT2CPT1A
SCHEMBL2000455 0.81 CA2 (0.49) ALDH1A1NPC1RAB9ASMN1; SMN2TP53
SCHEMBL14987871 0.77 RORC (0.51) RORCCPT2CPT1ACPT1BTP53
SCHEMBL2001990 0.76 GPR119 (0.44) GPR119RORCALDH1A1NPC1RAB9A
SCHEMBL1994714 0.76 RORC (0.46) GPR119RORCALDH1A1SMN1; SMN2CPT2
SCHEMBL1998709 0.75 CA2 (0.48) RORCALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL2002816 0.74 KMT2A (0.43) GPR119RORCALDH1A1CNR1CNR2
SCHEMBL2001224 0.73 NPC1 (0.48) GPR119RORCALDH1A1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960376-B2 Benzo-fused heterocycles CARA THERAPEUTICS, INC. (US) 2011-06-14 US claimed
US-7960376-B2 Benzo-fused heterocycles CARA THERAPEUTICS, INC. (US) 2011-06-14 US disclosed
US-7960376-B2 Benzo-fused heterocycles CARA THERAPEUTICS, INC. (US) 2011-06-14 US disclosed
US-20090075973-A1 BENZO-FUSED HETEROCYCLES CARA THERAPEUTICS, INC. (US) 2009-03-19 US disclosed
US-20090075973-A1 BENZO-FUSED HETEROCYCLES CARA THERAPEUTICS, INC. (US) 2009-03-19 US disclosed
WO-2009035997-A2 BENZO-FUSED HETEROCYCLES CARA THERAPEUTICS, INC. (US) 2009-03-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090075973-A1 BENZO-FUSED HETEROCYCLES CNR1, CNR2, TRPV1 GPR119 253/4885RORC 21/4885ALDH1A1 1422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.